Business
Notice of Results & Investor Presentation
Futura Medical plc announced that it will release its full year results for the year ended 31 December 2025 on Wednesday 29 April, with management hosting a webinar presentation on the same day at 10:00 BST via the Investor Meet Company platform. The company, known for its sexual health products like Eroxon®, is inviting existing and potential shareholders to attend the presentation, where questions can be submitted in advance or during the live event. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n 20 April 2026\n \nFutura Medical plc\n(\"Futura\" or the \"Company\")\nNotice of Results & Investor Presentation\n \nFutura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will release its full year results for the year ended 31 December 2025 on Wednesday 29 April.\nManagement will be hosting a webinar relating to the results via the Investor Meet Company platform on Wednesday 29 at 10:00 BST.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST the day before, or at any time during the live presentation.\nInvestors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor. Investors who already follow Futura on the Investor Meet Company platform will automatically be invited.\n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n\n\nAlexander Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\n \n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTurner Pope Investments (TPI) Ltd\nBroker\n\n\nGuy McDougall, Andrew Thacker\n\n\n+44 (0) 20 3657 0050\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett, Sam Modlin, Sarah Peters\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n \nNotes to Editors:\nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in the research, development and commercialisation of topically delivered gel formulations in sexual health products.\nSexual health issues are prevalent in both men and women. Erectile Dysfunction (\"ED\") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of a...